Yesterday Mulenga et al. published an article in Malaria Journal on the safety and efficacy of lumefantrine–artemether (Coartem® / Riamet®) for the treatment of uncomplicated Plasmodium falciparum malaria in Zambian adults, showing that this new first line regimen is far more efficient than Fansidar in treating uncomplicated malaria in adults.
Great, let's hope and pray that Coartem will become generally available throughout Zambia at affordable prices (one course currently goes for 7 pins and is rarely found in clinics or chemists).
Coartem is procured through who. The faq says:
Q: If this is humanitarian act by Novartis, why charge at all?
A: Novartis is charging on a not-for-profit basis, at a price which, primarily covers the cost of manufacture. At the special who price a treatment course costs us$2.4 for an adult and us$0.90 for the youngest age-group.
Posts
